Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06346509
PHASE1

Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of PORT-77 Administered to Healthy Adult Participants

Sponsor: Portal Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

A First-in-Human 2-part, randomized, double-blind, placebo-controlled, single ascending dose, multiple ascending dose, and food effect, investigation of the administration of PORT-77 in healthy adult participants.

Official title: A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose and Food Effect Study of PORT-77 Administered Orally to Healthy Adult Participants

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

108

Start Date

2024-04-08

Completion Date

2025-08-29

Last Updated

2025-04-04

Healthy Volunteers

Yes

Interventions

DRUG

PORT-77

Healthy adult participants will receive a single oral dose of PORT 77.

DRUG

Placebo

Healthy adult participants will receive matching placebo on Day 1.

Locations (1)

Celerion

Tempe, Arizona, United States